Skip to main content
. 2017 Apr 8;8(23):37409–37422. doi: 10.18632/oncotarget.16964

Figure 7. Valproate transiently recruits the transcriptional repressor EZH2 to the CD20 promoter in vivo but not in vitro.

Figure 7

I83-E95 cells were incubated with or without valproate (VPA) at 1000 μM for 72 hours and subjected to ChIP with anti-EZH2 antibody (A). Patient samples collected after 0 and 72 hours of valproate-treatment from cycle 1 (C) and cycle 2 (E) of the PREVAIL study were subjected to ChIP with anti-EZH2 antibody. Levels of EZH2 on the CD20 promoter were evaluated by densitometry analysis and expressed in graphs (B, D, F). (Mean values, bars ± s.e.m, n = 3; ns: not significant). Due to sample limitation, experiments C–F were performed once.